Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Intensification vs Alternating Triple Therapy in Poor Prognosis Lymphoma
NCT00002835Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 1995
- Primary completion
- Feb 2004
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ifosfamide, etoposide, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells, carmustine, cytarabine in non-Hodgkin lymphoma (NHL), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 1995; status: completed.
02
Drugs
ifosfamideetoposidemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cellscarmustinecytarabine
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00002835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002835.